Publicity Film of Digitized Chinese Materia Medica Standard ©2015 Chinese Pharmacopoeia Commission.
Establishing a digital platform for national drug standards focused on the Chinese Pharmacopoeia is an important step for the reform of China's drug standards management. By means of informatization, this platform will play an exemplary and motivational role in strengthening and improving the national drug standards system, upgrading the technology used in Chinese pharmaceutical industry, and improving the efficiency of standards management. In response, the Chinese Pharmacopoeia Commission is organizing and carrying out the construction of the digital drug standards system with financial support from the China Center for Food and Drug International Exchange since last year. This system is expected to lay a solid foundation for carrying out the goal of “building an informatization management platform for standards for national traditional Chinese medicine that can be shared by the society” as proposed in China’s Plan on Traditional Chinese Medicine Protection and Development (2015-2020). The first phase of the construction work is intended to build a digital standards system for traditional Chinese medicine that covers the contents of Chinese Pharmacopoeia, the ministerial standards, and local (provincial) standards. Read more»
The Digital Standards for Chinese Materia Medica version 1.0 includes the varieties of Chinese Materia Medica recorded in the volume I of the Chinese Pharmacopoeia and its Supplements, as well as contents of supporting series of Chinese Pharmacopoeia such as An Illustrated Handbook on Microscopic Identification of Chinese Crude Drugs, A Colored Identification Atlas of Chinese Materia Medica and Plants, Thin-layer Chromatography Atlas of Chinese Crude Drugs, High Performance Liquid Chromatography Atlas, and contains a total of 618 monographs for Chinese Materia Medica, and 3,452 various specialized illustrations for characters, microscopic identification and assay etc. The text of the Standards is available in both Chinese and English, and allows for a contrastive bilingual display. In addition, the software user interface is provided in multiple languages such as Chinese, English, French, German, and Japanese. It also collects records of the standards for traditional Chinese medicine (phytomedicine) that are maintained in the contemporary United States Pharmacopeia, European Pharmacopoeia, Japanese Pharmacopoeia, Indian Pharmacopoeia, Vietnamese Pharmacopoeia, and Korean Pharmacopoeia. The entire platform incorporated the concepts of “big data” and “internet plus” in its design and development in order to provide one-stop solutions and value-added information services associated with drug standards for the entire industry.
Through the joint efforts of the Chinese Pharmacopoeia Commission and relevant committee members, experts, and technical teams, the People's Medical Electronic Audio-Visual Publishing House has internationally released the Digital Standards for Chinese Materia Medica version 1.0. It is the first digital standard available for the field of traditional Chinese medicine. The Standards is anticipated to positively and profoundly accelerate the building of China’s independent and creative digital drug standard system, promote sustained improvement in Traditional Chinese Medicine quality standards, consolidate China’s authority over the formulation and international harmonization of standards for Traditional Chinese Medicine, improve the international competitiveness of the Traditional Chinese Medicine industry, as well as increase the international exchange of Traditional Chinese Medicine culture.
On the occasion of the Digital Standards for Chinese Materia Medica version 1.0 to be submitted for publication, I would like to thank committee members and experts Xie Peishan, Chen Shilin, Li Ping, and Lin Yulin for their considerable work on the compilation of Chinese Materia Medica atlas series.
It is a great pleasure to write this introduction.
Secretary General of the
Chinese Pharmacopoeia Commission
July 1, 2015
The national drug standard system with Chinese Pharmacopoeia as the core has been established in China, covering complete range of drug standards for Chinese crude drugs and prepared slices, patented Traditional Chinese Medicines, chemical drugs, biological products, pharmaceutical excipients, pharmaceutical packaging materials, etc. Chinese Pharmacopoeia is a reflection of the overall level of pharmaceutical industry development, drug quality and regulatory capacities in China, and plays a critical role in assuring drug quality, maintaining and guarding the well-being of the public and the legal interests of drug use, promoting healthy development of the pharmaceutical industry in China, as well as carrying out international harmonization and cooperation. Read more»
The Digitized Standards for Chinese Materia Medica, a medical accomplishment in the information age, is to date the most authoritative and comprehensive digital compilation of the Chinese national drug standards. The Standards is launched to provide a digital support platform so that users of Chinese Pharmacopoeia can comprehensively understand and study Chinese Materia Medica standards. Characteristics and advantages of this software are as follows: excellent reading experience, easy to carry and use, multiple languages supported, inquiry at any time and place, vast quantities of information, built-in national drug standard database containing photos, chromatograms and professional illustrations, powerful functions covering copying, marking, and retrieval and statistics, a flexible configuration for timely updates, and a reduction of social costs for the development and purchase of drug standards.
This Digitized Standards for Chinese Materia Medica also provides a personalized data service for pharmaceutical researchers (new drug developers, drug standard setters), producers and salesman (pharmaceutical and trading enterprises and medical institutions) and regulators (statutory drug inspection institutions and third-party labs) from different perspectives. For example: (1) retrieval function of revision and evolution process of drug standards; (2) fast query of synchronized records from the corresponding monograph in major pharmacopoeias through the built-in national drug standard database search engine; (3) comparison of Chinese and English versions of the monograph; (4) joint query of criteria for inspection, including monograph text, relevant testing methodology and supplementary chromatograms of drug standards; and (5) user online comment mechanism.
To take full advantage of value-added information service for drug standards, Chinese Pharmacopoeia Commission and publisher will timely provide users with standards update package and software service package based on the supplementation and revision of Chinese Materia Medica standards. Thus supporting the Digitized Standards for Chinese Materia Medica, as a dynamic database, to better serve the management, implementation and international harmonization of Chinese Materia Medica standards.
The publication of the Digitized Standards for Chinese Materia Medica has important and profound significance for further increasing the level of information integration of national drug standards and supporting works, enhancing the relevance of standard resources and digital management, promoting the richness, diversity and vividness of standards of Chinese Materia Medica, providing a new publication form of national drug standards, and better satisfying professional and social demands in aspects of regulation, inspection, scientific research, academic research, training and popularization.
Limited by ability and experience, the Digitized Standards for Chinese Materia Medica, a first systematic attempt to build digitized platform for national drug standards, certainly sees some mistakes and omission. If any, please inform us to deliver a better version together.
|兰 奋||（Lan Fen）||赵亚军||（Zhao Yajun）||薛 斌||（Xue Bin）|
|Yu Jiangyong（于江泳）||Ma Shuangcheng（马双成）||Wang Zhengtao（王峥涛）|
|Wang Hainan（王海南）||Shi Shangmei（石上梅）||Tian Runtao（田润涛）|
|Bai Jie（白洁）||Lan Fen（兰奋）||Ren Chongyuan（任重远）|
|Liu Chun（刘春）||Sun Lei（孙磊）||Li Ping（李萍）|
|He Wei（何畏）||Zhang Wei（张伟）||Zhang Jun（张军）|
|Zhang Tideng（张体灯）||Chen Shilin（陈士林）||Lin Yulin（林余霖）|
|Zhao Yajun（赵亚军）||Hong Xiaoxu（洪小栩）||Tang Lixin（唐立新）|
|Cao Lili（曹莉莉）||Tu Pengfei（屠鹏飞）||Xie Peishan（谢培山）|
|Zhai Weimin（翟为民）||Pan Lihua（潘丽华）||Xue Bin（薛斌）|
I. This Digitized Standards for Chinese Materia Medica was compiled by the Chinese Pharmacopoeia Commission, and developed by Chemmind Technologies, Co., Ltd., and is exclusively entrusted by Chinese Pharmacopoeia Commission. Read more»
II. The copyright of this Digitized Standards for Chinese Materia Medica (including but not limited to general notices, monographs, appendices, pictures of original plants, characteristic photos, powder and tissue photomicrographs, thin layer chromatography images, high performance liquid chromatography profiles, chromatographic fingerprints, etc.) is owned by the Chinese Pharmacopoeia Commission.
III. China Archives of Publications Index (ICP): (2015) No.051599, (2014) No.181305, (2013) No.169717, (2012) No.110847, (2011) No.083645, (2010) No.132489, (2009) No.202952, (2008) No.143176, (2008) No.143177.
IV. Literature citation format: Chinese Pharmacopoeia Commission. Digitized Standards for Chinese Materia Medica [M/CD], Beijing: People's Medical Electronic Audio-Visual Publishing House, 2015.
©2015 Chinese Pharmacopoeia Commission. All Rights Reserved. Any distribution, reproduction or duplication of this publication in part or in whole without written permission is expressly prohibited, and whoever violates this term shall be held for legal responsibilities.
I. We hereby declare that the information and illustrations (including but not limited to text, pictures of original plants, characteristic photos, powder and tissue photomicrographs, TLC chromatograms, HPLC chromatograms, chromatographic fingerprints, chemical reference substance structural formulas, etc.) contained in this Digitized Standards for Chinese Materia Medica are provided for the only purpose of helping readers understand and use Chinese Pharmacopoeia, and shall not be regarded as a legal basis or practical implementation standard, and we shall assume no legal responsibility on this account . Read more»
II. In case of any discrepancy between this Digitized Standards for Chinese Materia Medica and the printed edition of Chinese Pharmacopoeia as well as its supporting series, the latter shall prevail.
III. The Chinese Pharmacopoeia Commission reserves the right of the final interpretation of the Digitized Standards for Chinese Materia Medica.
IV. Users who install and use this Digitized Standards for Chinese Materia Medica shall be deemed as having accepted the terms and conditions of the end-user license agreement (EULA) covering the above copyright statement and disclaimer. If you do not agree with these terms, please do not install and use this software.
We are particularly grateful to members of the Chinese Pharmacopoeia Commission, as well as other experts, scholars and our colleagues for their tremendous contributions to the compilation of the Chinese Pharmacopoeia and supporting works. This Digitized Standards for Chinese Materia Medica contains the product of their collective intelligence. Read more»
Our special thanks are also extended to those pharmaceutical experts and colleagues who contributed invaluable assistance to the compilation and development of the Digitized Standards for Chinese Materia Medica.
This work was supported by the Chinese Drug Regulation System Improvement and Professionals Training Project (Year 2015-2017) of the China Center for Food and Drug International Exchange.
Chinese Pharmacopoeia Commission